Table 2.
Outcome | VA Test AUC (95% Cl) | UM Test AUC (95% Cl) | ||||
---|---|---|---|---|---|---|
All | Female | Male | All | Female | Male | |
Multiclass | ||||||
Original VA model | 0.9742(0.9718, 0.9770) | 0.9691(0.9413, 0.9846) | 0.9744(0.9721, 0.9777) | 0.8685(0.8644, 0.8726) | 0.8689(0.8612, 0.8738) | 0.8680(0.8620, 0.8740) |
AKI-1+ | ||||||
Incidence | 3.53%(23,957/678,516) | 2.00%(745/37,226) | 3.62(23,212/641,290) | 3.76%(58,382/1,551,354) | 3.18%(24,585/772,665) | 4.34%(33,797/778,689) |
Original VA model | 0.8196(0.8168, 0.8223) | 0.7943(0.7770, 0.8116) | 0.8194(0.8166, 0.8222) | 0.8469(0.8453, 0.8484) | 0.8477(0.8453, 0.8501) | 0.8439(0.8419, 0.846) |
AKI-2+ | ||||||
Incidence | 0.41 %(3,277/806,465) | 0.34%(139/40,855) | 0.41 %(3,138/765,610) | 0.86%(15,076/1,753,474) | 0.75%(6,472/857,809) | 0.96%(8,604/895,665) |
Original VA model | 0.7741(0.7656, 0.7825) | 0.7636(0.7191, 0.8080) | 0.7749(0.7663, 0.7835) | 0.6550(0.6494, 0.6606) | 0.6504(0.6419, 0.6590) | 0.6622(0.6549, 0.6695) |
AKI-3+ | ||||||
Incidence | 0.22%(1,775/821,316) | 0.21 %(88/41,443) | 0.22%(1,687/779,873) | 0.39%(6,976/1,790,447) | 0.32%(2,780/875,621) | 0.46%(4,196/914,826) |
Original VA model | 0.8341(0.8248, 0.8433) | 0.7111(0.6520, 0.7703) | 0.8393(0.8300, 0.8486) | 0.7981(0.7919, 0.8044) | 0.7627(0.7518, 0.7737) | 0.8271(0.8198, 0.8345) |
AKI-3D | ||||||
Incidence | 0.11 %(940/839,964) | 0.15%(61/42,071) | 0.11 %(879/797,893) | 0.08%(1,412/1,817,604) | 0.07%(586/887,574) | 0.09%(826/930,030) |
Original VA model | 0.9497(0.9429, 0.9565) | 0.8927(0.8251, 0.9602) | 0.9537(0.9487, 0.9588) | 0.9558(0.9507, 0.9609) | 0.9560(0.9480, 0.9641) | 0.9550(0.9483, 0.9618) |